Tecfidera Headwinds Could Mean Cuts At Biogen, Unless Aducanumab Succeeds

 
• By Jessica Merrill

Biogen lowered revenue guidance for the year by $600m due to Tecfidera generics and said it could consider broader cost cuts in 2021 depending on the outcome of aducanumab at the US FDA.

opened yellow scissors over turquoise blue background
Biogen may have cost cuts ahead in 2021 • Source: Shutterstock

More from Strategy

More from Business